Not all hemp-derived CBD topicals are created equal
Cannidex is tested, packaged, and processed in Colorado, USA using ingredients that are manufactured under GMP, NSF and ISO certified processes. It is developed using hemp-derived CBD crystal registered and regulated by the Colorado State Department of Agriculture. The hemp plants are grown and distributed in full compliance with the State of Colorado, as well as in full federal compliance with §7606 of the 2014 US Farm Bill. Because CANNIDEX™ contains only CBD—not THC—it has no psychoactive effect and will not cause someone to get “high.”
Potency: CANNIDEX™ delivers 1500 mg of CBD in each 50 g topical formulation.
Purity: Unlike other CBD formulations, CANNIDEX™ is made from 99% pure hemp crystals, not from hemp-CBD oils.4
Targeted Therapy: CANNIDEX™ – applied to the body or at the back of the neck—safely delivers CBD through the skin in a clinically proven patented topical cream.
Safety Focus: CANNIDEX™ is co-developed, backed and used by a recognized neurologist and produced in a state-of-the-art facility overseen by licensed pharmacists.
Odorless: No cannabis-related smell, no artificial dyes or fragrances.
Eco-Friendly: Waste-free airless dispenser delivers a precise amount with minimal residue in patented self-sealing container that reduces contamination, dry-out and discoloration.
For patent pending Direct Effects™ method:
Apply 1-2 pumps (1-2g) to the back of the neck, starting at the hairline, working down toward the muscles just below the neck.
“A ground-breaking topical drug therapy which treats neurologic and psychiatric conditions, including chronic pain, through direct nerve connections without limitations of blood flow; thereby providing rapid therapeutic benefits without concerns of systemic side effects and drug interactions.” 6
DR. RONALD AUNG-DIN, MD HAS BEEN USING A DIRECT EFFECTSTM TOPICAL HEMP-DERIVED CBD CREAM IN CLINICAL PRACTICE.1
In a study of 88 patients, 1-2 pumps of topical CBD applied to the back of the neck was found to be effective in treating the symptoms of the following conditions
- Encephalopathy(including lethargy, inattention, and cognition)
- Pain(including radiculopathy and shingles)
- Anxiety and other mood disorders(including PTSD)
- Parkinson’s disease
- Bell’s palsy and facial nerve dysfunction
- Trigeminal neuralgia
- Hemi-facial spasm
- Attention deficit disorder & hyperactivity
- Social isolation
- Occipital neuralgia
- TMJ dysfunction-related symptoms
- Cognitive problems(including memory disturbance)
- Peripheral neuropathy
- Essential tremor
The Food and Drug Administration has not evaluated the statements made regarding CANNIDEX™. The efficacy of CANNIDEX™ has not been confirmed by FDA-approved research and CANNIDEX™ is not intended to diagnose, treat, cure or prevent any disease. No information presented here is intended to be a substitute for, or alternative to, information from a health care provider. Please consult your health care provider about potential interactions or other possible complications before using CANNIDEX™.
CANNIDEX™ is a trademark of Cannidex Brands, LLC. Direct Effects™ is a trademark of AfGin Pharma, LLC.
CANNIDEX™ Brands, LLC is a licensee of United States Patent Application No. 62126757, filed in March 2015 by inventor Ronald Aung-Din and currently pending with the USPTO. This patent covers the application of topical hemp derived CBD at the back-of-the-neck (BON) region through Direct Effects™. No FDA-approved clinical trials have been conducted with any Direct Effects™ CBD topical formulation.